$43.03−0.66 (−1.51%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$42.91−0.12 (−0.28%)
After hours: Nov 17, 2026, 7:58 PM ET
Boston Scientific (BSX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~14.0%/yr (FY21→FY25), net margin 14.4%, and free cash flow (~$3.7B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▲19.9%
20.1
FY21→FY25CAGR +14.0%/yr
Net income ($B)▲56.3%
2.9
one-off year: see footnoteCAGR +29.2%/yr
Free cash flow ($B)▲38.3%
3.7
FY21→FY25CAGR +29.1%/yr
Diluted EPS▲55.2%
1.94
FY21→FY25CAGR +29.5%/yr
What the receipts whisper · what a headline number hides
Share count
+4.2%
1.4bn → 1.5bn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$876.0M
steady at 4.4% of revenue (+10.9% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
14¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 68.8% → 69.0%. Net margin 14.4% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 21,068.0 | 20,074.0 | 16,747.0 | 14,240.0 | 12,682.0 | 11,888.0 | ▲19.9% | +14.0% |
Cost of revenue | 6,502.0 | 6,221.0 | 5,257.0 | 4,345.0 | 3,956.0 | 3,711.0 | ▲18.3% | +13.8% |
Gross profit | 14,568.0 | 13,854.0 | 11,490.0 | 9,896.0 | 8,727.0 | 8,177.0 | ▲20.6% | +14.1% |
Research & development | 2,159.0 | 2,052.0 | 1,615.0 | 1,414.0 | 1,323.0 | 1,204.0 | ▲27.1% | +14.3% |
Selling, general & admin | 7,100.0 | 6,887.0 | 5,984.0 | 5,190.0 | 4,520.0 | 4,359.0 | ▲15.1% | +12.1% |
Total operating expenses | 10,637.0 | 10,241.0 | 8,887.0 | 7,553.0 | 7,079.0 | 6,978.0 | ▲15.2% | +10.1% |
Operating incomefeeds ROC rank | 3,932.0 | 3,613.0 | 2,603.0 | 2,343.0 | 1,649.0 | 1,199.0 | ▲38.8% | +31.8% |
Other income, net | −277.0 | −228.0 | −321.0 | −358.0 | −508.0 | −123.0 | — | — |
Pretax income | 3,655.0 | 3,385.0 | 2,282.0 | 1,985.0 | 1,141.0 | 1,076.0 | ▲48.3% | +33.2% |
Income tax | 163.0 | 493.0 | 436.0 | 393.0 | 443.0 | 36.0 | ▲13.1% | +92.4% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 3,502.0 | 2,898.0 | 1,854.0 | 1,593.0 | 698.0 | 1,041.0 | ▲56.3% | +29.2% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.36 | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 | ▲55.2% | +29.5% |
Diluted shares (bn) | 1.45 | 1.49 | 1.49 | 1.46 | 1.44 | 1.43 | ▲0.6% | +1.0% |
| Margins | ||||||||
Gross margin56th pct in Healthcare | 69.1% | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | ▲0.4pp | +0.2pp |
Operating margin | 18.7% | 18.0% | 15.5% | 16.5% | 13.0% | 10.1% | ▲2.5pp | +7.9pp |
Net margin79th pct in Healthcare | 16.6% | 14.4% | 11.1% | 11.2% | 5.5% | 8.8% | ▲3.4pp | +5.7pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 3% vs a 19% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 39% vs a 19% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Boston Scientific's revenue last fiscal year?
Boston Scientific reported revenue of $20.1B in fiscal 2025, up 19.9% from fiscal 2024.
What was Boston Scientific's net income?
Boston Scientific reported net income of $2.9B in fiscal 2025, a net margin of 14.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

